在第23届美国东部乳腺癌未来国际年会上,医学博士Bruce G. Haffty提出了对新辅助化疗后淋巴结阳性转为阴性的乳腺癌患者省略放射治疗的考虑。 在2023年圣安东尼奥乳腺癌研讨会上发表的NRG/NSABP B-51/RTOG 1304期试验(NCT01872975)的结果显示,在59.5个月的中位随访中,接受区域淋巴结照射的患者的估计5年浸润性乳腺癌...
Julian,Thomas B. Julian,Atif J. Kahn,Atif J. Kahn 展开 摘要: This phase III randomized post-NC trial will evaluate if CWRNRT after mastectomy (Mx) or whole breast irradiation (WBI) with RNRT after breast-conserving surgery (BCS) significantly reduces the rate of IBCR-FI in pts who ...
NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to ...